SUPPORT AGREEMENTSupport Agreement • May 12th, 2022 • Skye Bioscience, Inc. • Pharmaceutical preparations • Nevada
Skye Bioscience Signs Arrangement Agreement with Emerald Health Therapeutics Arrangement is expected to fund Skye’s proprietary synthetic cannabinoid- derivative therapeutic initially targeting glaucoma for first Phase 2 clinical study planned to...Skye Bioscience Signs Arrangement Agreement • May 12th, 2022 • Skye Bioscience, Inc. • Pharmaceutical preparations
San Diego, California, May 12, 2022 -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”) and Emerald Health Therapeutics, Inc. (CSE: EMH; OTCQB: EMHTF) (“Emerald”) announced today that the companies have entered into a definitive agreement with respect to a transaction to be completed by way of a Plan of Arrangement (the “Arrangement”) whereby Skye would acquire all of the issued and outstanding shares of Emerald in a share-for-share-transaction. Skye is a San Diego-based pharmaceutical company developing proprietary, synthetic cannabinoid derivatives to treat glaucoma and other diseases with significant unmet needs. Emerald possesses cash and non-cash assets that Skye would acquire through the Arrangement. The proposed Arrangement is subject to approval by each company’s common stockholders and by the Supreme Court of British Columbia, Canada.
ARRANGEMENT AGREEMENT BETWEEN SKYE BIOSCIENCE, INC. AND EMERALD HEALTH THERAPEUTICS, INC. May 11, 2022Arrangement Agreement • May 12th, 2022 • Skye Bioscience, Inc. • Pharmaceutical preparations • British Columbia
(a)the SKYE Board (as hereinafter defined) has established a special committee thereof consisting only of independent and disinterested directors (the “SKYE Special Committee”) to, among other things, consider and negotiate the Agreement and the transactions contemplated hereby;
